"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Eisai Inc.","Eisai","$11,000,000","$0","$11,000,000","2010","20101215","healthcare-related offenses","off-label or unapproved promotion of medical products","","Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran",""
"Eisai","Eisai","$7,634,700","$0","$7,634,700","2000","20001011","competition-related offenses","price-fixing or anti-competitive practices","","Six international vitamin companies agreed to pay a total of $255 million to settle multistate litigation accusing them of conspiring to fix prices. The settlement agreement linked below lists the percentages of the total applicable to each defendant; they were used to determine the penalty amounts in the individual company entries here. The companies reached a separate $85 million agreement with California. These are covered in separate Violation Tracker entries.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","http://app3.naag.org/antitrust/search/viewCivilLitigation.php?trans_id=182",""
"Eisai","Eisai","$1,000,000","$0","$1,000,000","2013","20131118","government-contracting-related offenses","False Claims Act and related","","The Louisiana Attorney General's Office announced that it had obtained a total of $88 million in settlements from 25 pharmaceutical companies to resolve allegations they overcharged the state's Medicaid program.","state","agency action","Louisiana Attorney General","civil","","","","","","Louisiana","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131206104321/http://www.ag.state.la.us/Article.aspx?articleID=788&catID=2",""
"Eisai Co.","Eisai","$2,544,900","$0","$2,544,900","2000","20001010","competition-related offenses","price-fixing or anti-competitive practices","","The California Attorney General reached an $85 million with six major vitamin producers to resolve international price-fixing allegations. This was separate from a $255 million settlement the companies reached with a group of other states. The California announcement did not indicate how the $85 million would be apportioned among the defendants. We assume here that it divided up according to the same percentages used in the larger settlement.","state","agency action","California Attorney General","civil","","","","","","California","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.oag.ca.gov/news/press-releases/attorney-general-lockyer-announces-80-million-antitrust-settlement-involving",""
"Eisai Co.","Eisai","$111,167","$0","$111,167","2002","20020904","competition-related offenses","price-fixing or anti-competitive practices","","Hoffman-La Roche Inc. and Roche Vitamins Inc.; BASF Corporation; Aventis Animal Nutrition S.A., formerly Rhone-Poulenc Animal Nutrition S.A.; Takeda Chemical Industries, Ltd.; Eisai Co., Ltd.; and Daiichi Pharmaceutical Co., Ltd. agreed to jointly pay $667,000 in settlement of allegations they enaged in price fixing of vitamins. The Commonwealth of Massachusetts did not participate in the multistate settlement in October 2000 and instead made claims for antitrust damages under the Massachusetts Consumer Protection Act. The announcement did not indicate how much each company would pay. Here we assume the amount was divided equally among them.","state","agency action","Massachusetts Attorney General","civil","","","","","","Massachusetts","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20020928141823/http://www.ago.state.ma.us/press_rel/vitamins.asp",""
"Eisai Inc.","Eisai","$4,658,249","$4,658,249","$0","2010","20101216","healthcare-related offenses","off-label or unapproved promotion of medical products","False Claims Act and related","Japanese drug marketer Eisai Inc. agreed to pay $4.6 million to settle multistate litigation concerning the off-label marketing of the epilepsy drug Zonegran. This was part of a larger $11 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-eisai-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran",""
"EISAI INC.","Eisai","$6,376","$0","$6,376","2010","20100114","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Massachusetts","ANDOVER","4 CORPORATE DRIVE","01810","325412","325412: Pharmaceutical Preparation Manufacturing","Japan","","publicly traded","","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
